Lv DD, et al. - Among genotype-2 (GT-2) patients receiving sofosbuvir (SOF)+NS5A inhibitors, researchers studied the virological response and liver fibrosis improvement. Between March 2016 and July 2017, patients who received SOF+NS5A inhibitors were enlisted. The results of this retrospective study indicated that SOF+NS5A inhibitor therapies in patients infected with hepatitis C virus (HCV) GT-2 can induce excellent virological response and improvement in fibrosis.